SLGL Sol-Gel Technologies Ltd.
Price Chart
Executive Summary
Sol-Gel reported Q1 2026 revenue of $0.1M (down 89.5% YoY from $1.0M) and a net loss of $3.7M ($1.31/share), improved from a $8.8M loss in Q1 2025. The company highlighted a Notice of Allowance for a method-of-use patent extending SGT-610 protection to 2044, an oversubscribed $33.1M offering, and an exclusive license agreement with Sun Pharma for TWYNEO in India. Cash and marketable securities totaled $52.8M, funding operations into Q1 2028.
Actionable Insight
The sharp revenue decline and reliance on non-recurring milestones make the legacy product business difficult to value, but the $33.1M capital raise and patent extension de-risk SGT-610 through its Phase 3 readout in Q4 2026. Traders should watch for top-line results from the Gorlin syndrome trial, which is the primary catalyst; a positive readout could re-rate the stock significantly, while a miss would likely erase the post-offering premium.
Key Facts
- Q1 2026 revenue was $0.1M, down from $1.0M in Q1 2025, primarily due to the absence of a milestone payment from Searchlight.
- Net loss improved to $3.7M ($1.31/share) from $8.8M ($3.2/share) in Q1 2025, driven by a $6.0M reduction in R&D expenses.
- Cash, cash equivalents, and marketable securities totaled $52.8M as of March 31, 2026, up from $24.0M at year-end 2025.
- Completed an oversubscribed underwritten offering in March 2026, raising gross proceeds of approximately $33.1M.
- Received a Notice of Allowance from the USPTO for a method-of-use patent covering topical patidegib (SGT-610), extending IP protection to 2044.
- Pivotal Phase 3 trial of SGT-610 for Gorlin syndrome remains on track for top-line results in Q4 2026.
- Signed an exclusive license agreement with Sun Pharma for TWYNEO commercialization in India.
- Shares outstanding increased from 2,786,158 at December 31, 2025 to 3,268,991 at March 31, 2026, reflecting dilution from the offering.
- Management expects TWYNEO and EPSOLAY launches in most new territories during 2028 and 2027, respectively, with potential annual royalty revenue of ~$10M by 2031.
Financial Impact
Revenue declined $0.9M YoY; net loss improved by $5.1M; cash position increased by $28.8M from year-end 2025 due to $33.1M offering; share count increased ~17% from the offering.
Risk Factors
- Phase 3 trial failure or delay would severely impact the stock, as SGT-610 is the primary value driver.
- Revenue from legacy products (TWYNEO/EPSOLAY) remains minimal and unpredictable, with launches not expected until 2027-2028.
- Dilution from the March 2026 offering (~17% increase in shares outstanding) weighs on per-share metrics.
- Cash runway only extends to Q1 2028, requiring further financing if SGT-610 commercialization is delayed.
Market Snapshot
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001178913-26-002963 |
| Document: zk2635418.htm | 0001178913-26-002963 |
| Document: 0001178913-26-002963-index-headers.html | 0001178913-26-002963 |
| Document: 0001178913-26-002963-index.html | 0001178913-26-002963 |
| Document: 0001178913-26-002963.txt | 0001178913-26-002963 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
May 28, 2026
12d ago
|
6-K
| $75.28 $71.50 | ▼ −5.02% | ▼ −4.97% | $80.00 (+6.27%) |
|
May 28, 2026
12d ago
|
Press Release
| $75.28 $71.50 | ▼ −5.02% | ▼ −4.97% | $80.00 (+6.27%) |
|
Mar 24, 2026
11w ago
|
EFFECT
| $80.01 $79.22 | ▼ −0.99% | ▼ −0.56% | $80.00 (−0.01%) |
|
Mar 19, 2026
11w ago
|
Press Release
| $81.71 $77.75 | ▼ −4.85% | ▼ −2.63% | $80.00 (−2.09%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access